Cabometyx
An oral targeted therapy used to treat kidney, thyroid, and liver cancers.
Where Cabozantinib is approved
All regulators →Of the three regulators tracked here, the first to approve Cabozantinib was the EU, on 21 Mar 2014. It is approved in 3 of the 3 regulators tracked here.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
What health systems spend on Cabozantinib
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Cabozantinib works
All drug targets →- Vascular endothelial growth factor receptor 2 inhibitor InhibitorTarget: KDR kinase insert domain receptor✓ In ChEMBL and the Guide to Pharmacology
- Hepatocyte growth factor receptor inhibitor InhibitorTarget: MET MET proto-oncogene, receptor tyrosine kinase✓ In ChEMBL and the Guide to Pharmacology
- Carcinoid tumorPhase 3
- Clear cell renal carcinomaPhase 3
- Differentiated thyroid carcinomaPhase 3
- Neuroendocrine neoplasmPhase 3
- Non-small cell lung carcinomaPhase 3
- Prostate cancerPhase 3
- Renal cell adenocarcinomaPhase 3
- OsteosarcomaPhase 2/3
- Ewing sarcomaPhase 2
- Merkel cell skin cancerPhase 2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL2105717, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3), ligand 5887, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
NICE appraisals of Cabozantinib
All NICE appraisals →NICE, which decides whether the NHS in England should fund new medicines, has published 7 technology appraisals of Cabozantinib. 6 are current, and 5 of these recommend it for at least some patients. 1 older appraisal was replaced or withdrawn.
| Appraisal | NICE recommendation | Published | Status |
|---|---|---|---|
| Cabozantinib with nivolumab for untreated advanced renal cell carcinoma NICE TA964 | Optimised | 10 Apr 2024 | Current |
| Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine NICE TA928 | Not recommended | 1 Nov 2023 | Current |
| Cabozantinib for previously treated advanced hepatocellular carcinoma NICE TA849 | Optimised | 14 Dec 2022 | Current |
| Cabozantinib for untreated advanced renal cell carcinoma NICE TA542 | Recommended | 3 Oct 2018 | Current |
| Cabozantinib for treating medullary thyroid cancer NICE TA516 | Recommended | 28 Mar 2018 | Current |
| Cabozantinib for previously treated advanced renal cell carcinoma NICE TA463 | Recommended | 9 Aug 2017 | Current |
NICE decisions apply to the NHS in England. In Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics. Titles, categories and dates link to the guidance on nice.org.uk. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
Patient leaflets for Cabozantinib
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- IEIreland: 3 products on the HPRA listEach product record links to the HPRA, which publishes the leaflet and SmPC.
- EU
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Cabozantinib
- ATC code
- L01XE26
- ChEMBL
- CHEMBL2105717
- DrugBank
- DB08875
- PubChem CID
- 25102847
- CAS number
- 849217-68-1
- FDA UNII
- 1C39JW444G
- Wikidata
- Q795057
- Wikipedia
- Cabozantinib
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
What Cabometyx is used for
CABOMETYX is a kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma (RCC). ( 1.1 ) patients with advanced renal cell carcinoma, as a first-line treatment in combination with nivolumab ( 1.1 ) patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib ( 1.2 ) adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible ( 1.3 ) adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET). ( 1.4 ) adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastat…
How it works
12.1 Mechanism of Action In vitro biochemical and/or cellular assays have shown that cabozantinib inhibits the tyrosine kinase activity of MET, VEGFR-1, -2 and -3, AXL, RET, ROS1, TYRO3, MER, KIT, TRKB, FLT-3, and TIE-2. These receptor tyrosine kinases are involved in both normal cellular function and pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, drug resistance, and maintenance of the tumor microenvironment.
Related clinical trials recruiting now
Compare Cabometyx with
Explore more
How this page is built
The facts on this page are pulled directly from official U.S. FDA datasets — they are not written from memory. Each field below names the dataset it came from, so you can check it yourself.
- FDA Drug Label (openFDA) ↗ Indications, mechanism of action and pharmacologic class
- Drugs@FDA ↗ First FDA approval date and the company holding the application
- FDA Drug Shortage Database ↗ Current US supply / shortage status
Plain-English summaries and drug-class explainers are written and reviewed by Sreepriya Prasannan (MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany). Data is retrieved automatically from the sources above and cross-checked with AI-assisted verification (Anthropic's Claude) — brand and generic names are matched against the exact FDA product record so that a combination product or a different formulation cannot be mistaken for the drug on this page. An editor reviews the result before publication. We describe this in full in our editorial standards and corrections policy. The FDA data on this page was last retrieved on 6 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.